Celldex Therapeutics (CLDX) Amortizatization of Intangibles (2010 - 2026)

Celldex Therapeutics' Amortizatization of Intangibles history runs 17 years deep, the most recent figure standing at $630000.0 for Q1 2026.

• In Q1 2026, Amortizatization of Intangibles fell 72.21% year-over-year to $630000.0; the TTM figure through Mar 2026 stood at $4.2 million (down 71.31% YoY), while the FY2025 annual figure was $5.9 million, down 62.82% from the prior year.
• Amortizatization of Intangibles for Q1 2026 stood at $630000.0, down from $882000.0 in the prior quarter.
• The five-year high for Amortizatization of Intangibles was $4.7 million in Q2 2024, with the low at -$772000.0 in Q1 2022.
• The 5-year median for Amortizatization of Intangibles is $1.3 million (2023), against an average of $1.6 million.
• The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles sank 1708.33% in 2022, then soared 2905.17% in 2023.
• Celldex Therapeutics' Amortizatization of Intangibles stood at $522000.0 in 2022, then soared by 317.43% to $2.2 million in 2023, then jumped by 54.34% to $3.4 million in 2024, then plunged by 73.77% to $882000.0 in 2025, then retreated by 28.57% to $630000.0 in 2026.
• Business Quant data shows CLDX's Amortizatization of Intangibles at $630000.0 in Q1 2026, $882000.0 in Q4 2025, and $1.0 million in Q3 2025.